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ABSTRACT: Novel scaﬀolds are of uttermost importance for the
discovery of functional material. Three diﬀerent heterocyclic
scaﬀolds easily accessible from isocyanoacetaldehyde dimethyla-
cetal 1 by multicomponent reaction (MCR) are described. They
can be eﬃciently synthesized by a Ugi tetrazole multicomponent
reaction of 1. We discuss the synthesis, 3D structures, and other
physicochemical properties.
Novel scaﬀolds form the basis for success in the discoveryof bioactive compounds, which eventually can be
developed to drugs for the treatment of unmet medical
needs. A decade ago the NIH started an initiative (Molecular
Libraries Program (MLP)) to assemble a large chemical library
to be screened by academic institutions to yield, after
optimization, in vitro tool compounds (molecular probes) for
novel targets showing activity and selectivity in cell based
systems.1 These tool compounds can be accessed by interested
researchers and are of importance to elucidate the interplay of
novel targets in biology and disease.2 The European Lead
Factory (ELF), a public private partnership, is a complementary
European initiative with similar targets aiming for a library of
500 000 novel compounds by 2017.3 The availability of
molecular probes (small molecule or antibody) has been
recently and impressively demonstrated to be a key
determinant of progress in basic biology and disease areas.4
From a practical point of view the synthesis of medium sized
high quality libraries is demanding. The use of a “universal
building block” in the synthesis of diﬀerent scaﬀolds has great
advantages in the parallel synthesis of larger libraries. For
example, unprotected α-amino acids have been used recently in
diﬀerent multicomponent reaction chemistry to stereoselec-
tively aﬀord a diversity of novel cyclic and acyclic scaﬀolds,
including amido-aminophosphonates,5 boneratamide ana-
logues,6 iminodicarboxamides,7 iminobenzazocineacetamide,8
boropeptides,9 thiolactone and thiomorpholino, diketopipera-
zines,10 seleno amino acid,11 imidazol,12 or indol derivatives.13
Isocyanide 1 as its diethyl acetal was ﬁrst described by
Hardtke in 1966 and now robust large scale syntheses exist.14
Competitive analysis shows few applications of the building
block 1 in heterocycle synthesis toward 1-aryl-2-arylthio-1H-
imidazoles and imidazo[1,5-a]imidazoles (Scheme 1).15 Other
scaﬀolds reported include thiazoles and chiral imidazoles both
by a thio Ugi reaction.16 Here we describe the easy synthesis of
diﬀerent scaﬀolds 2−4 using the same easily accessible building
block 1, while not compromising diversity aspects.
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Scheme 1. Previously Elaborated Heterocyclic Scaﬀold
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We envisioned that tetrazole annulated piperazine scaﬀold 2
could be accessed from the Ugi-tetrazole reaction using
isocyanide building block 1, primary amines 5, aldehydes or
ketones 6, and TMSN3 7 (Scheme 2) and subsequent
cyclization/elimination via the secondary amine. In the
optimization campaign the reaction is performed in methanol
at ambient temperature. The Ugi adduct 8 was further treated
with neat acetic acid at 80 °C but did not yield the cyclized
product 2. Similar results were obtained with triﬂuoroacetic
acid, methanesulfonic acid with and without solvents such as
CH2Cl2, CH3CN, and toluene at 50−80 °C. However, the Ugi-
adduct 8 stirred with neat methanesulfonic acid for 18 h at
ambient temperature aﬀorded scaﬀold 2 in good yields.
In general, the Ugi reaction works well with aromatic and
aliphatic aldehydes and ketones. In the post-Ugi reaction we
observed that aliphatic aldehyde, ketones, and electron-deﬁcient
benzaldehydes could be used to give the product 2 in good
yield. Electron-rich benzaldehydes also worked, however giving
the desired product in low yields (2c). Typical examples are
shown in Table 1.
When more electron-rich benzaldehydes (10) are used the
intermediate Ugi tetrazole product undergoes a diﬀerent
cyclization pathway and can be reacted further to yield
tetrazolo-phenyl-azepine scaﬀold 3 involving a o-phenol
addition and elimination (Scheme 3). 3,5-Dimethoxy benzal-
dehyde gives better yields then 3,4,5-trimethoxy and 3,4-
dimethoxy benzaldehydes. Generally both primary and
secondary amines used gave moderate to good yields while
the use of anilines caused the yield of our desired product to
drop (3h). Typical examples and yields are shown in Table 2.
The use of electron-rich 2-(heteroaromatic)ethylamines 13
allows for access to polycyclic scaﬀold 4. The intermediate Ugi
tetrazole 14 yet undergoes a diﬀerent reaction pathway and can
be further reacted in a Pictet−Spengler transformation
according to Scheme 4. Various aldehydes and ketones were
tested, and all generated the product in satisfactory yields
(Table 3). In most cases the products were obtained as a single
major diastereomer; however, in the case of tryptophan methyl
ester the Ugi products were obtained as a diastereomeric
mixture of 14i (3:2) and 14j (2:1) and corresponding cyclized
products 4i (9:1) and 4j (2:1).
Next we investigated the structure of exemplary compounds
of each scaﬀold in the solid state (Figure 1). We could grow
three crystals of 2e, 3c, and 4f suitable for single crystal
structure determination conﬁrming the scaﬀold design and
showing intermolecular interactions.
With the general synthesis of these scaﬀolds we set forth to
create a virtual library of all three tetrazole reactions to analyze
Scheme 2. Designed Synthetic Pathway to Tetrazolo
Piperazine Scaﬀold 2
Table 1. Typical Structures and Yields of Scaﬀold 2
aIsolated yields for Ugi reaction and cyclization.
Scheme 3. Designed Synthetic Pathway to Benzotetrazolo
Azepinamine Scaﬀold 3
Table 2. Typical Structures and Yields of Scaﬀold 3
aIsolated yields for Ugi reaction and cyclization.
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some of their general physicochemical features. We randomly
generated 1000 examples of each scaﬀold. To visualize the
distribution in a 3D chemical space unbiased molecular
descriptors were analyzed by principal component analysis
(PCA) (Figure 2B and Supplemental Figure 2). Interestingly,
even though these scaﬀolds are all derived from the same ﬁrst
Ugi tetrazole multicomponent reaction they possess very
diﬀerent characteristics in terms of their chemical space due
to their connectivity, substitution pattern, and ring sizes. To
visualize this diﬀerence, 3D generation and alignment of the
tetrazole ring on all three scaﬀolds was done (Figure 2A). As
can be seen, due to the diﬀerent rings that stem from the
tetrazole base the three scaﬀolds each occupy a diﬀerent space.
To study this concept further we performed the principal
moment of inertia (PMI)17 analysis to compare the shape
distribution of our virtual library of small molecules to that of
1000 randomly selected compounds from the ZINC library18
(Supplemental Figure 1). As expected, based on the previous
data, the three scaﬀolds occupy diﬀerent 3D spaces and tend to
be more 3D in nature to compounds from the ZINC database.
The three-dimensionality of lead compounds recently emerged
as an important concept to provide “drug-like” properties, e.g.
reduced promiscuity or water solubility.19 Interestingly, scaﬀold
2 occupies a wider array of space compared to scaﬀolds 3 and 4
which cluster closer together. This is most likely due to the
substitution pattern on scaﬀold 2, using two widely variable
starting materials.
Scheme 4. Designed Synthetic Pathway to Pyridotetrazolo
Piperazine Scaﬀold 4
Table 3. Typical Structures and Yields of Scaﬀold 4
aIsolated yields for Ugi reaction and cyclization. bDr ratio was
determined by SFC-MS and 1H NMR.
Figure 1. 3D structure of examples of scaﬀolds 2−4 in the solid state.
Figure 2. (a) Overlay of energy-minimized conformers of the
backbones of the three scaﬀolds described in this paper (green =
scaﬀold 2, blue = scaﬀold 3, orange = scaﬀold 4). (b) 2D principal
component analysis of 1000 randomly generated compounds of each
of the three scaﬀolds described in this paper (green = scaﬀold 2, blue =
scaﬀold 3, red = scaﬀold 4).
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Work is ongoing to leverage the new chemical space to




Physical and computational data can be found in the
Supporting Information. This material is available free of
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2014, 21, 2143−2151.
(14) Hartke, K. Chem. Ber. 1966, 99, 3163−3172.
(15) (a) Bossio, R.; Marcaccini, S.; Pepino, R. Liebigs Ann. Chem.
1993, 1229−1231. (b) Bossio, R.; Marcaccini, S.; Pepino, R.; Torroba,
T. J. Org. Chem. 1996, 61, 2202−2203.
(16) (a) Gulevich, A. V.; Balenkova, E. S.; Nenajdenko, V. G. J. Org.
Chem. 2007, 72, 7878−7885. (b) Kazmaier, U.; Ackermann, S. Org.
Biomol. Chem. 2005, 3, 3184−3187.
(17) Sauer, W. H.; Schwarz, M. K. J. Chem. Inf. Comput. Sci. 2003, 43,
987−1003.
(18) (a) Irwin, J. J.; Shoichet, B. K. J. Chem. Inf. Model. 2005, 45,
177−82. (b) Irwin, J. J.; Sterling, T.; Mysinger, M. M.; Bolstad, E. S.;
Coleman, R. G. J. Chem. Inf. Model. 2012, 52, 1757−68.
(19) Lovering, F.; Bikker, J.; Humblet, C. J. Med. Chem. 2009, 52,
6752−6756.
Organic Letters Letter
dx.doi.org/10.1021/ol5024882 | Org. Lett. 2014, 16, 5736−57395739
